Lyophilized Injectable Drugs Market to Gather Pace from Strides in Biopharmaceuticals Manufacturing, Global Valuation to Expand at CAGR of 6.7% during 2018 - 2026 TMR
- Rise in investments on contract research manufacturing services (CRAMS) by drug-making companies boost lyophilized injectable drugs market
- Prevalence of metabolic disorders drives optimization of the process of lyophilisation of injectables, demand for new drug formulations for chronic disease management spurs demand in North America
ALBANY, N.Y., March 2, 2021 /PRNewswire/ -- Lyophilization is a crucial process for injectable for achieving a stable drug product and in ensuring an adequate biological activity. The process regulates numerous key drug product quality attributes such as the cake stability during storage and transportation. A majority of biopharmaceutical such as proteins, vaccines, antibodies, enzymes, biologics, peptides, and plasma need to undergo adequate lyophilisation before commercialization. The process is also being used for some diagnostic reagents, especially those used in IVD. Types of packaging used for lyophilized injectable drugs are single-use vials, point-of-care reconstitution, and specialty packaging, with single-use vials are expected to witness vast opportunity during the forecast period of 2018 – 2026.
The lyophilized injectable drugs market has seen a growing array of processes that affect different parameters at each drug development stage. Outsourcing of these services has thus gained a huge impetus from the growing number of contract research manufacturing services (CRAMS).
The lyophilized injectable drugs market stood at US$ 2,300 Mn in 2017 and is slated to rise at CAGR of 6.7% from 2018 to 2026.
Request for Analysis of COVID-19 Impact on Lyophilized Injectable Drugs Market – https://www.transparencymarketresearch.com/covid19.php
Key Findings of Lyophilized Injectable Drugs Market Study
Advances in Biopharmaceuticals Formulation Present Vast Potential
Incredible strides that biopharmaceuticals manufacturing has made in the drug-making industry present a vast scope for the commercialization of formulations in the lyophilized injectable drugs market. Need for improving the stability of biopharmaceuticals has led to continuous advances in the formulation, notably for proteins. New approaches have come to the core to support these initiatives. A key trend spurring biopharmaceuticals manufacturing is the rise in number of contract research manufacturing services (CRAMS). Growing demand for biologics and protein-based therapeutics for treating diseases has cemented investments in CRAMs.